Zacks Research Upgrades Monopar Therapeutics (NASDAQ:MNPR) to “Strong-Buy”

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other research firms have also recently weighed in on MNPR. Piper Sandler set a $105.00 price target on Monopar Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. BTIG Research raised their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research note on Monday, March 30th. Three analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $108.75.

Monopar Therapeutics Trading Down 3.4%

Shares of NASDAQ:MNPR opened at $99.79 on Monday. The firm has a market cap of $668.59 million, a PE ratio of -52.52 and a beta of 1.46. The company has a fifty day simple moving average of $72.95 and a 200 day simple moving average of $64.26. Monopar Therapeutics has a 12-month low of $29.18 and a 12-month high of $112.57.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.41. As a group, equities research analysts forecast that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its holdings in shares of Monopar Therapeutics by 2.3% during the fourth quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after purchasing an additional 30,042 shares during the period. RA Capital Management L.P. increased its stake in Monopar Therapeutics by 30.5% in the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after buying an additional 156,000 shares during the period. Siren L.L.C. lifted its position in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after buying an additional 30,370 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Monopar Therapeutics during the 3rd quarter valued at $18,904,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.